Exagen Inc. (XGN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Exagen Inc. on March 23, 2023, covering an event that occurred on March 20, 2023. The Company is incorporated in Delaware and its common stock trades on The Nasdaq Global Market under the symbol "XGN".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The material change reported is the resignation of James L.L. Tullis from the Board of Directors. His resignation is effective at the Company's 2023 annual meeting of stockholders. The Company stated that Mr. Tullis' decision to resign was not due to a disagreement with the Board or the Company on any matter relating to operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding financial guidance, future outlook, specific risks, contingencies, or unusual items. The sole purpose of this filing is to disclose the departure of a director.
Key Facts for Investor Verification
- James L.L. Tullis is resigning from the Board of Directors effective at the 2023 annual meeting of stockholders.
- The resignation is not attributed to any disagreement with the Company or its Board.
- The report was signed by Kamal Adawi, Chief Financial Officer, on March 23, 2023.
- No financial data or operational metrics are included in this specific filing.